קומירנטי PBS ישראל - עברית - Ministry of Health

קומירנטי pbs

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines

קומירנטי 30 TRIS ישראל - עברית - Ministry of Health

קומירנטי 30 tris

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

נורווסק 5 מג טבליות ישראל - עברית - Ministry of Health

נורווסק 5 מג טבליות

pfizer pfe pharmaceuticals israel ltd - amlodipine as besylate - טבליה - amlodipine as besylate 5 mg - amlodipine - amlodipine - mild to moderate hypertension. vasospastic angina ( prinzmetal's or variant angina). chronic stable angina.

סוטנט 12.5 מג ישראל - עברית - Ministry of Health

סוטנט 12.5 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 12.5 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 25 מג ישראל - עברית - Ministry of Health

סוטנט 25 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 25 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

סוטנט 50 מג ישראל - עברית - Ministry of Health

סוטנט 50 מג

pfizer pharmaceuticals israel ltd - sunitinib as malate - קפסולות - sunitinib as malate 50 mg - sunitinib - sunitinib - sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. sutent is indicated for the treatment of advanced renal cell carcinoma.treatment of unresectable or metastatic, well differentiated pancreatic neuroendocrine tumours (pnet) with disease progression.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 200 מג ישראל - עברית - Ministry of Health

קסאלקורי 200 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.

קסאלקורי 250 מג ישראל - עברית - Ministry of Health

קסאלקורי 250 מג

pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.